leadf
logo-loader
viewIMV Inc.

ImmunoVaccine's target stock price is jacked up by Mackie analyst

Andre Uddin of Mackie also opts to keep a Speculative Buy rating on the stock

pills
IMV’s reverse split took effect on May 2

An application to list on the Nasdaq as well as its recent 3:2:1 reverse stock split are pushing a Mackie Research analyst to raise his target stock price on ImmunoVaccine Inc (TSX:IMV), the Canadian clinical stage immune-oncology group, to C$8.70.

Andre Uddin is also keeping a Speculative Buy rating on the stock.

Next month, IMV’s researchers will present the top-line results of an ongoing Phase 1b study, which is testing its cancer vaccine DPX-Survivac in combination with the oncology research group Incyte’s 300mg epacadostat, a fledgling IDO1 inhibitor, to treat patients with advanced ovarian cancer.

Additional results from clinical trials are also expected from IMV in the third quarter.

 IMV and Incyte have also opted to open a Phase2 study to evaluate the effectiveness of DPX-Survivac and low-dose cyclophosphamide with or without epacadostat in patients suffering from advanced ovarian cancer that has recurred.

 IMV’s reverse split took effect on May 2 and its post-consolidation trading on the TSX is set to kick off on May 10.

Shares in ImmunoVaccine Inc added 2.5% to C$1.58 Thursday.

Quick facts: IMV Inc.

Price: 4.66 CAD

TSX:IMV
Market: TSX
Market Cap: $309.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Water Tower Research Managing Director talks trends in the Communications...

Water Tower Research Managing Director John Roy joined Steve Darling from Proactive to discuss the trends he is seeing the communications sector including the emergence of 5G. Roy also told Proactive about some other interesting things he is seeing including the amount of people working from...

9 minutes ago

2 min read